Author Topic: European Commission approves Ocrevus for early PPMS  (Read 63 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8216
  • MS diagnosed 1980
  • Location: Pacific Northwest
European Commission approves Ocrevus for early PPMS
« on: January 26, 2018, 09:46:57 pm »

The European Commission has approved Ocrevus for use in early PPMS. What is meant by "early PPMS" isn't spelled out but there is this statement in an article about the approval of Ocrevus by the EMA (European Medicines Agency):


Quote
The EMA is recommending that for PPMS, ocrelizumab should only be prescribed for people with early PPMS, according to the duration of their MS symptoms, their level of disability and whether their MRI results indicate inflammatory activity. The EMA notes that more investigation is required before this treatment can be recommended for people in more advanced stages of disability.

"First treatment in Europe approved for early primary progressive MS," from the MS International Federation, January 24, 2018:


https://www.msif.org/news/2018/01/12/first-treatment-europe-approved-early-primary-progressive-ms/?lang=en
« Last Edit: January 26, 2018, 09:48:45 pm by agate »
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
1 Replies
76 Views
Last post December 07, 2016, 03:02:57 pm
by agate
1 Replies
97 Views
Last post August 21, 2017, 05:28:11 pm
by agate
0 Replies
55 Views
Last post June 04, 2018, 10:08:38 am
by agate
0 Replies
38 Views
Last post June 26, 2018, 02:57:59 pm
by agate
0 Replies
2 Views
Last post Today at 09:44:00 pm
by agate